Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
507 participants
OBSERVATIONAL
2007-10-15
2015-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* We also wish to evaluate more thoroughly lipid anomalies associated with the presence of steatosis, notably with regard to monocyte expression of LDL receptors. We hypothesize that hepatic steatosis is accompanied by activation of transcription factors involved in lipogenesis, notably SREBP factors. The activation of these factors could cause an increase in the expression of LDL receptors, leading to increased LDL catabolism.
* Chronological description of the study During an outpatient consultation at the endocrinology department, diabetic patients, programmed to undergo an examination to assess their diabetes will be invited to participate in the study. Once written informed consent has been provided and clinical data has been recorded, patients with type 1 or type 2 diabetes will have standard biological examination, which is systematically done in such patients (Fasting glycemia, HBA1c, aspartate aminotransferase, alanine amino transferase, Gammaglutamyl-transferases, PAL, bilirubin, blood proteins, albuminemia, Total Cholesterol total, HDL cholesterol, triglycerides, Sedimentation Rate, C-reactive protein, fibrinogen).
As well as the systematic biological tests, 3 additional tubes will be taken to screen for genetic polymorphism in 3 proteins (Microsomal Transfer Protein, Adiponectin receptor - 1, Apolipoprotein A - II).
IN addition, magnetic resonance imaging and magnetic resonance spectroscopy will be done to look for the presence of liver steatosis and to measure carotid intima-media thickness.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of a New Gene Involved in Hereditary Lipodystrophy
NCT02056912
A Biological Atlas of Severe Obesity (Biological Tissue Collection)
NCT01129297
The Role of Dietary Carbohydrate and Fat Availability in the Regulation of Hepatic Lipid Content
NCT04581421
Trancriptomics and Lipidomics of Epicardial Ectopic Fat
NCT06590415
Characteristics of NAFLD Among Type 2 Diabetes Patients
NCT04999124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with type-1 diabetes
prise de sang
magnetic resonance imaging and magnetic resonance spectroscopy
Patients with type-2 diabetes
prise de sang
magnetic resonance imaging and magnetic resonance spectroscopy
Volontaires sains
prise de sang
magnetic resonance imaging and magnetic resonance spectroscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prise de sang
magnetic resonance imaging and magnetic resonance spectroscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1C\>6.5%
* 27\<BMI\<55
* Type 1 diabetes
* BMI\<55 Diagnosis of type-1 diabetes based on the clinical history of the patient and/or the presence of anti-glutamate decarboxylase auto antibodies and/or a plasma level of C peptide below 0,5 ng/l.
* Non diabetic
* Alcohol consumption \< 2 glasses per day
* Without hyperglycemic treatment (corticoids, ...)
* Without liver disease (cirrhosis, hepatitis, ...)
Exclusion Criteria
* Daily alcohol consumption above 4 glasses per day
* Patients treated with Glitazones during the 3 months preceding inclusion
* Presence of implants
* Claustrophobia
* Patient \< 18 years
* Patient under guardianship or not intellectually independent
* Pregnancy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de DIJON
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PETIT PARI 2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.